Technology | Prostate Cancer | November 10, 2016

Augmenix Announces New Category 1 CPT Code for Periprostatic Implantation of Biodegradable Material

New AMA code establishes a standard reimbursement pathway for this new procedure performed with SpaceOAR technology

Augmenix, SpaceOAR System, prostate cancer, new CPT code, AMA, American Medical Association

November 10, 2016 — Augmenix Inc. announced that the American Medical Association (AMA) has granted a Category I, Current Procedural Terminology (CPT) code specifically for periprostatic implantation of biodegradable material. AMA granted the code with the support of the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA).

The purpose of CPT is to provide a uniform language that accurately describes medical, surgical and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients and third parties. The new CPT code is expected to become effective on Jan. 1, 2018 at which time the Category III code, 0438T, will be eliminated.

Following the recent presentation of positive three-year data from the SpaceOAR Pivotal Clinical Trial at the 2016 ASTRO Annual Meeting in Boston, AMA granted a Category 1 CPT code for periprostatic implantation of biodegradable material.

“SpaceOAR is clearly the most elegant and clinically proven technology for reducing rectal toxicity in the treatment of prostate cancer developed in the past 20 years,” said Steven Kurtzman, M.D., president, Western Radiation Oncology Inc., San Mateo, Calif. “I consider the product an integral part of my treatment protocol for patients receiving both external beam radiation therapy and brachytherapy.”

The leading side effects of prostate cancer radiotherapy are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, urgency, pain, etc.), which results from unintended radiation injury to the rectum (the Organ At Risk, OAR). These complications can last for years, significantly impacting patient quality of life (QOL).

Using a minimally invasive procedure, Augmenix’s SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed by the body after radiotherapy is complete.

The SpaceOAR System is U.S. Food and Drug Administration (FDA)-cleared. It is also CE marked, approved in Australia and licensed in Canada.

For more information: www.augmenix.com

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV) #coronavirus #nCoV2019 #2019nCoV #COVID19

Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV). Three representative axial thin-section chest CT images show multifocal ground glass opacities without consolidation. Three-dimensional volume-rendered reconstruction shows the distribution of the ground-glass opacities (arrows). Image courtesy of the Radiological Society of North America (RSNA)

News | Radiology Imaging | February 25, 2020
February 24, 2020 — The U.S.
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Esaote, an Italian company among the world leaders in the field of medical diagnostic imaging systems, is the Ducati Team's official partner for the 2020 season
News | Radiology Business | February 14, 2020
February 14, 2020 — Esaote, an Italian company among the world le
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...